Want to see BEAM full AI Analyst Report?
Beam-301: Single Dose Of Beam-301 Administered By Iv
Glycogen Storage Disease Type Ia
Phase I/II
Recruiting
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
Dec 06, 2024
―
Beam-302
Alpha 1-Antitrypsin Deficiency
Phase I/II
Recruiting
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
Apr 22, 2024
―
Beam-201
Lymphoblastic Lymphoma, Lymphoblastic Leukemia, T-Cell Lymphoblastic Leukemia/Lymphoma
Phase I/II
Active Not Recruiting
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
May 23, 2023
―
Beam-101
Sickle Cell Disease
Phase I/II
Recruiting
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
Jun 23, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Beam Therapeutics (BEAM) have in its pipeline
BEAM is currently developing the following drugs: Beam-301: Single Dose Of Beam-301 Administered By Iv, Beam-302, Beam-201. These drug candidates are in various stages of clinical development as the company works toward FDA approval.